An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

The present disclosure relates to production of recombinant RNA molecules encoding an oncolytic virus genome, such as a picornavirus, with native 5 end of the viral genome utilizing ribozymes. The present disclosure further relates to the design of corresponding DNA template and the use of the recombinant RNA molecules and/or corresponding particles for the treatment and prevention of cancer.

An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.

Provided herein are compositions and methods of using Seneca Valley Virus (SVV) or a derivative thereof and an interferon type I (IFN-I) inhibiting agent comprising an mTOR inhibitor for treating a cancer in a subject. The disclosed methods particularly rely upon the expression level of an ANTXR1 and the expression level of IFN-I in the cancer from the subject. Also provided herein are methods for predicting the efficacy of an SVV treatment comprising IFN-I inhibiting agent.